Business
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive momentum.Pharmaceuticals Division sales increased by 9% (3% in CHF), with Phesgo (breast cancer), Xolair (food allergies), Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Vabysmo (severe eye diseases) being the top growth drivers.Diagnostics Division sales grew 2% (-3% in CHF) as demand
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2)
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TdqKHuoAMRswPfW7YQ22wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Sales in the fourth quarter increased by 8%, reflecting the positive momentum.","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharmaceuticals Division sales increased by 9% (3% in CHF), with Phesgo (breast cancer), Xolair (food allergies), Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Vabysmo (severe eye diseases) being the top growth drivers.","length":232,"tagName":"p"}]},{"val":[{"type":"text","content":"Diagnostics Division sales grew 2% (-3% in CHF) as demand for pathology and molecular solutions continued to more than offset the impact of healthcare pricing reforms in China.","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Core operating profit increased by 13% (5% in CHF), driven by higher sales and efficiency gains.","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Core earnings per share showed growth of 11% (4% in CHF); IFRS net income increased by 58% (50% in CHF), due to the strong operational performance in 2025 and the base effect of impairment charges in 2024.","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"US and EU approval for the subcutaneous form of Lunsumio for a type of blood cancer","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"EU approval for Gazyva/Gazyvaro for lupus nephritis, a serious kidney disease","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive data on several therapies: (phase III) giredestrant for breast cancer, fenebrutinib for ...